Says Bilchick, This study adds to our knowledge of the effect of these GLP-1 receptor agonists on reducing morbidity, mortality, and now, in this large study, reducing incident atrial fibrillation over the long term. More research is still needed, especially regarding how different GLP-1 medications, doses, and treatment durations affect weight loss, inflammation, glucose control, Afib risk, and long-term cardiovascular health
The CV safety of OW CagriSema in 7000 patients with overweight or obesity and established CV disease will be evaluated in the REDEFINE-3 clinical trial (NCT05669755)
NO System Modulation: BPC-157 provides counter-regulatory mechanismupregulating NO when deficient, moderating when excessivemaintaining vascular homeostasis in damaged tissue models
It contributes to maintaining a healthy weight and optimal nutrient absorption
The gains are real
Our healthcare team will carefully assess your medical history to determine whether compounded Semaglutide is safe for you